Published in Thromb Haemost on June 01, 1999
Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. Blood (2009) 2.07
The Prophylaxis of Venous Thromboembolism. Dtsch Arztebl Int (2016) 1.36
Incidence and risk factors for development of venous thromboembolism in Indian patients undergoing major orthopaedic surgery: results of a prospective study. Postgrad Med J (2006) 1.15
Common variants of large effect in F12, KNG1, and HRG are associated with activated partial thromboplastin time. Am J Hum Genet (2010) 1.15
Obesity increases length of stay and direct medical costs in total hip arthroplasty. Clin Orthop Relat Res (2013) 1.07
Risk factors for pulmonary embolism after hip and knee arthroplasty: a population-based study. Int Orthop (2008) 1.03
Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer. Br J Cancer (2008) 0.98
Rotational thromboelastometry predicts thromboembolic complications after major non-cardiac surgery. Crit Care (2014) 0.87
Prospective study of plasma D-dimer and incident venous thromboembolism: The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Res (2015) 0.82
A gene-centric analysis of activated partial thromboplastin time and activated protein C resistance using the HumanCVD focused genotyping array. Eur J Hum Genet (2012) 0.82
Genetic polymorphisms in venous thrombosis and pulmonary embolism after total hip arthroplasty: a pilot study. Clin Orthop Relat Res (2008) 0.81
Genetic polymorphism of NOS3 with susceptibility to deep vein thrombosis after orthopedic surgery: a case-control study in Chinese Han population. PLoS One (2013) 0.77
The relationship of the factor V Leiden mutation or the deletion-deletion polymorphism of the angiotensin converting enzyme to postoperative thromboembolic events following total joint arthroplasty. BMC Musculoskelet Disord (2001) 0.75
A Review on the Management of Hip and Knee Osteoarthritis. Int J Chronic Dis (2013) 0.75
Factors that may influence the functional outcome after primary total hip arthroplasty. Clujul Med (2013) 0.75
Markers of thrombin generation during resurfacing and noncemented total hip arthroplasty: a pilot study. Clin Orthop Relat Res (2011) 0.75
By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ (1994) 11.85
The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet (2002) 10.52
Detecting and describing heterogeneity in meta-analysis. Stat Med (1998) 8.44
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med (1999) 6.88
Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet (1986) 6.51
Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet (1997) 6.48
Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol (1987) 6.20
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med (1997) 6.19
Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ (1998) 6.07
Outbreak of hepatitis A among Italian patients with haemophilia. Lancet (1992) 5.64
Assessing possible hazards of reducing serum cholesterol. BMJ (1994) 5.61
Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men. Lancet (2000) 5.61
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet (1994) 5.58
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet (1994) 5.45
Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med (1995) 5.24
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med (1999) 5.14
Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost (2000) 4.81
Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med (2000) 4.81
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med (1996) 4.70
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost (2006) 4.58
Carbenoxolone sodium in the treatment of gastric ulcer with special reference to side-effects. Gut (1965) 4.56
Incidence and aetiology of heart failure; a population-based study. Eur Heart J (1999) 4.56
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med (2001) 4.33
Does breathing other people's tobacco smoke cause lung cancer? Br Med J (Clin Res Ed) (1986) 4.06
Seasonal variation in arterial blood pressure. Br Med J (Clin Res Ed) (1982) 3.82
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest (1987) 3.73
Analysis and interpretation of cost data in randomised controlled trials: review of published studies. BMJ (1998) 3.71
Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet (2001) 3.69
Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate. Lancet (1985) 3.53
Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J (2001) 3.49
The benefits and harms of breast cancer screening: an independent review. Br J Cancer (2013) 3.43
Haemostatic function and cardiovascular death: early results of a prospective study. Lancet (1980) 3.25
Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med (1982) 3.16
Guidelines for management of left-sided prosthetic valve thrombosis: a role for thrombolytic therapy. Consensus Conference on Prosthetic Valve Thrombosis. J Am Coll Cardiol (1997) 3.06
Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost (2006) 3.03
The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet (1989) 2.97
Survival of patients with a new diagnosis of heart failure: a population based study. Heart (2000) 2.86
Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales. Stat Med (2002) 2.86
Eliminating parvovirus B19 from blood products. Lancet (1994) 2.85
Uncertain times for research on hemophilia and allied disorders. J Thromb Haemost (2005) 2.74
Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med (2002) 2.73
Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation (1999) 2.59
A likelihood approach to meta-analysis with random effects. Stat Med (1996) 2.54
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med (2001) 2.54
Hospitalization of patients with heart failure: a population-based study. Eur Heart J (2002) 2.54
Effects of exposure to air pollution on blood coagulation. J Thromb Haemost (2006) 2.52
Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med (1998) 2.49
Change in coronary risk and coronary risk factor levels in couples following lifestyle intervention. The British Family Heart Study. Arch Fam Med (1997) 2.41
A comparison of real-time compression ultrasonography with impedance plethysmography for the diagnosis of deep-vein thrombosis in symptomatic outpatients. N Engl J Med (1993) 2.39
High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med (2000) 2.39
Age at last full-term pregnancy and risk of breast cancer. Lancet (1993) 2.34
Atomic force microscopy: a novel approach to the detection of nanosized blood microparticles. J Thromb Haemost (2009) 2.33
High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med (1998) 2.30
Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen. J Cell Biol (1988) 2.28
Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation (1998) 2.26
Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. J Thromb Haemost (2014) 2.15
Analysis of a cluster randomized trial with binary outcome data using a multi-level model. Stat Med (2000) 2.14
Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation (2004) 2.12
Meta-analysis of continuous outcome data from individual patients. Stat Med (2001) 2.07
Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. N Engl J Med (1980) 2.07
A multilevel model framework for meta-analysis of clinical trials with binary outcomes. Stat Med (2000) 2.06
1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet (1977) 2.06
Fifteen-year follow-up of a randomized clinical trial of ultrasonographic screening for abdominal aortic aneurysms. Br J Surg (2007) 2.04
Should the frequency of surveillance for small abdominal aortic aneurysms be reduced? Eur J Vasc Endovasc Surg (2013) 2.04
Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost (1999) 2.04
Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med (1983) 2.03
Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood (1996) 2.02
Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding. J Thromb Haemost (2005) 2.02
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
The Lancet's statistical review process: areas for improvement by authors. Lancet (1992) 2.00
The putative factor IX gene promoter in hemophilia B Leyden. Blood (1988) 1.98
The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med (1999) 1.97
Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet (1993) 1.96
The relation between treatment benefit and underlying risk in meta-analysis. BMJ (1996) 1.96
Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood (1996) 1.88
Clinical trial of deglycyrrhizinized liquorice in gastric ulcer. Gut (1969) 1.88
Idiopathic gangrene in African children. Br Med J (1967) 1.85
von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost (2006) 1.84
Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost (1996) 1.83
Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study. BMJ (2007) 1.81
C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation (2001) 1.81
Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood (1999) 1.81
Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med (1991) 1.81
Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation (1996) 1.80
A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost (2011) 1.75
Side chains that influence fidelity at the polymerase active site of Escherichia coli DNA polymerase I (Klenow fragment). J Biol Chem (1999) 1.71
Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. Am J Epidemiol (1996) 1.70
Final 12-year follow-up of surgery versus surveillance in the UK Small Aneurysm Trial. Br J Surg (2007) 1.70